SCHEMBL5546111

SCHEMBL5546111

CC(O)(COC(=O)N1CCN(c2ccc(Cl)c(Cl)c2)CC1)Cn1cc([N+](=O)[O-])nc1Cl

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.53
MAPK1 P28482 2/20 0.53
HTT P42858 2/20 0.53
SMN1; SMN2 Q16637 6/20 0.47
LMNA P02545 5/20 0.42
ALDH1A1 P00352 2/20 0.42
RAB9A P51151 1/20 0.42
MGLL Q99685 1/20 0.41
KCNH2 Q12809 1/20 0.38
SIGMAR1 Q99720 1/20 0.38
KMT2A Q03164 1/20 0.37
GRIN1 Q05586 1/20 0.37
GRIN2B Q13224 1/20 0.37
TSHR P16473 1/20 0.37
TP53 P04637 1/20 0.37
POLB P06746 1/20 0.37
ENPP2 Q13822 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5546105 1.00 MAPT (0.53) MAPTMAPK1HTTSMN1; SMN2LMNA
SCHEMBL5546002 0.91 LMNA (0.46) MAPTMAPK1HTTSMN1; SMN2LMNA
SCHEMBL5546006 0.91 LMNA (0.46) MAPTMAPK1HTTSMN1; SMN2LMNA
SCHEMBL5545923 0.91 ENPP2 (0.45) MAPTMAPK1HTTSMN1; SMN2LMNA
SCHEMBL5545919 0.91 ENPP2 (0.45) MAPTMAPK1HTTSMN1; SMN2LMNA
SCHEMBL5542473 0.90 MAPT (0.45) MAPTMAPK1HTTSMN1; SMN2LMNA
SCHEMBL5542481 0.90 MAPT (0.45) MAPTMAPK1HTTSMN1; SMN2LMNA
SCHEMBL5537206 0.89 MAPT (0.46) MAPTMAPK1HTTSMN1; SMN2LMNA
SCHEMBL5537217 0.89 MAPT (0.46) MAPTMAPK1HTTSMN1; SMN2LMNA
SCHEMBL5534954 0.88 ENPP2 (0.45) MAPTMAPK1HTTSMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 MAPT 4117/4885MAPK1 1392/4885HTT 4644/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.